文献速递胃肠外科围术期管理与 ERAS

GERD药物与手术患者的CYP2C19基因变异差异

Genetic variations in medical versus surgical patients with GERD: beyond PPIs and fundoplications.
PubMed 文献 · Surg Endosc · 2026-06-05

本研究为多中心回顾性队列研究,纳入2012至2023年261例GERD患者,比较药物与手术治疗者CYP2C19表型分布。手术患者快代谢/超快代谢表型比例显著高于药物患者,提示PPI抵抗可能与基因变异相关。

要点

  • 手术GERD患者CYP2C19快/超快代谢型比例显著高于药物患者
  • 药物患者中快/超快代谢型可考虑PPI剂量递增
  • PPI无效时应及时转诊评估抗反流手术

核心结论

  • 手术治疗的GERD患者中CYP2C19快代谢和超快代谢表型患病率高于药物治疗患者。

研究设计与样本

  • 多中心回顾性队列研究,纳入2012至2023年261例GERD并接受CYP2C19基因分型的成人患者。
  • 药物组187例,手术组74例,比较CYP2C19表型分布。

主要发现

  • 手术患者快代谢/超快代谢表型比例显著高于药物患者(p = 0.018)。
  • 药物与手术患者食管裂孔疝大小差异显著(p < 0.001)。
  • 药物组中Barrett食管占52%,异常pH检测占31%,LA C/D级食管炎占17%。

临床怎么用

  • 对药物治疗的GERD患者,若存在快代谢/超快代谢表型,可考虑增加PPI剂量。
  • 若剂量递增无效,应及时转诊评估抗反流手术。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Gastroesophageal Reflux Disease (GERD) is treated primarily with proton pump inhibitors (PPIs), with surgery reserved for patients refractory to PPIs or with symptomatic hiatal hernias. PPI efficacy depends on metabolism by cytochrome P450 2C19 (CYP2C19) in the liver, which varies with genetic polymorphisms. Rapid (RM) and ultra-rapid (UM) metabolizers may require higher PPI doses for efficacy, while poor (PM) and intermediate (IM) metabolizers respond to lower doses but have higher risk of side effects. This study assesses CYP2C19 phenotype prevalence in medically versus surgically managed GERD. We hypothesized a higher RM/UM rate among surgical patients, suggesting PPI resistance. METHODS: This was a multi-site retrospective cohort study of adult patients with GERD and CYP2C19 genotyping from 2012 to 2023. Medical patients included those with Barrett's esophagus, LA grade C/D esophagitis, or abnormal pH testing. Surgical patients included those who underwent anti-reflux surgery. CYP2C19 phenotypes were grouped as PM/IM, normal metabolizer (NM), and RM/UM based on the anticipated need for PPI dose adjustment. Descriptive statistics were used for analysis. RESULTS: A total of 261 patients were included in this study: 187 medical (female: 59%, mean age: 57 (SD 15), 77% White) and 74 surgical (female: 69%, mean age: 58 (SD 13), 89% White). Medical patients included the following esophageal pathologies: 52% Barrett's esophagus, 31% abnormal pH testing, and 17% LA grade C/D esophagitis. Surgical patients had a significantly higher proportion of RM/UM phenotypes compared to medical patients (p = 0.018). There was also a significant difference in hiatal hernia size between medical and surgical patients (p < 0.001). CONCLUSION: Surgical patients have a higher prevalence of hypermetabolizing (RM/UM) CYP2C19 phenotypes compared to medical patients. Dose escalation of PPI should be considered in medical patients with these phenotypes, and if ineffective, a timely referral for anti-reflux surgery should be made.

来源:Surg Endosc,查看原文。版权归原作者所有。

引用

  1. Naser AR, Pather K, Mobley EM, et al. Genetic variations in medical versus surgical patients with GERD: beyond PPIs and fundoplications. Surg Endosc. 2026. PMID: 42247133. doi:10.1007/s00464-026-12904-4

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。